Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Inhibitors, Agonists, Antagonists, Activators & Modulators

1,4-Dicaffeoylquinic acid

(1,4-DCQA) Cat. No.: HY-N0358

1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid from Xanthii fructus, inhibits LPS-stimulated TNF-α production.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

13-Methylberberine chloride

(13-Methylberberinium chloride) Cat. No.: HY-125827

13-Methylberberine chloride (13-Methylberberinium chloride), a berberine analogue, has anti-adipogenic and antitumor activities.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

5(S)15(S)-DiHETE

Cat. No.: HY-113492

5(S)15(S)-DiHETE is an "activated" intermediate, inhibits platelet aggregation with an IC_{50} of 1.3 μM. 5(S)15(S)-DiHETE enhances the rate of either LXA4 or LXB4 biosynthesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7,3',4'-Tri-O-methylluteolin

(5-Hydroxy-3',4',7-trimethoxyflavone) Cat. No.: HY-N7012

7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone), a flavonoid compound, possesses potent anti-inflammatory effects in LPS-induced macrophage cell line mediated by inhibition of release of inflammatory mediators, NO, PGE2, and...



Purity: 99.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

A-9758

Cat. No.: HY-126252

A-9758 is a RORγ ligand and a potent, selective **RORγt** inverse agonist (IC_{50}=5 nM), and exhibits robust potency against **IL-17A** release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-YVAD-CHO

(L-709049) Cat. No.: HY-120019

Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-Iβ converting enzyme (**ICE**) inhibitor with mouse and human K_i values of 3.0 and 0.76 nM. Ac-YVAD-CHO can suppress the production of mature IL-Iβ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AF12198

Cat. No.: HY-P1110

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC_{50}=8 nM) but not the human type II receptor (IC_{50}=6.7 μM) or the murine type I receptor (IC_{50}>200 μM).

Purity: 99.61%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apilimod

(STA 5326) Cat. No.: HY-14644

Apilimod (STA 5326) is a potent **IL-12/IL-23** inhibitor, and strongly inhibits IL-12 with IC_{50}s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. Apilimod is a potent and highly selective **PIKfyve** inhibitor.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apilimod mesylate

(STA 5326 mesylate) Cat. No.: HY-14644A

Apilimod (STA 5326) mesylate is a potent **IL-12/IL-23** inhibitor, and strongly inhibits IL-12 with IC_{50}s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. Apilimod is a potent and highly selective **PIKfyve** inhibitor.



Purity: 99.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

APY0201

Cat. No.: HY-15982

APY0201 is a potent **PIKfyve** inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P_2 in the presence of in the presence of [^{33}P]ATP with an IC_{50} of 5.2 nM. APY0201 also inhibits **IL-12/IL-23** production.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Armillarisin A

Cat. No.: HY-108013

Armillarisin A has the potential for the ulcerative colitis (UC) study. Armillarisin A increases IL-4 and lower IL-1β.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg

AX-024

Cat. No.: HY-107390

AX-024 is an orally available, first-in-class inhibitor of the **TCR-Nck** interaction that selectively inhibits TCR-triggered T cell activation with an IC_{50} ~1 nM. AX-024 modulates cell signaling by targeting **SH3** domains.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AX-024 hydrochloride

Cat. No.: HY-107390A

AX-024 hydrochloride is an orally available, first-in-class inhibitor of the **TCR-Nck** interaction that selectively inhibits TCR-triggered T cell activation with an IC_{50} ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting **SH3** domains.



Purity: 99.12%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Balsalazide

Cat. No.: HY-B0667

Balsalazide could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Balsalazide sodium hydrate

(Balsalazide disodium dihydrate)

Cat. No.: HY-B0667A

Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Balsalazide-d4

Cat. No.: HY-B0667S1

Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benralizumab

(MEDI-563; BIW-8405)

Cat. No.: HY-P9923

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity.

Benralizumab

Purity: ≥99.1%
Clinical Data: Launched
Size: 1 mg, 2 mg

BIRT 377

Cat. No.: HY-110117

BIRT 377 is a potent amd orally bioavailable inhibitor of the interaction between intercellular adhesion molecule-1 (ICAM-1) and **lymphocyte function-associated antigen-1 (LFA-1)**, with a K_i of 25.8 nM. BIRT 377 also inhibits the production of IL-2 in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-986251

Cat. No.: HY-136527

BMS-986251 is an orally active and selective **RORγt** inverse agonist with an EC_{50} of 12 nM for RORγt GAL4. BMS-986251 inhibits **IL-17** with an EC_{50} of 24 nM in human whole blood assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD6989

Cat. No.: HY-122586

BRD6989, an analog of the natural product cortistatin A (dCA), inhibits **CDK8** and upregulates **IL-10**. BRD6989 selectively binds a complex of CDK8 with an IC_{50} of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C6 L-threo Ceramide

Cat. No.: HY-116609

C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. C6 L-threo Ceramide significantly inhibits IL-4 production in T cells. Anti-allergic agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cis-Mulberroside A

(Mulberroside D)

Cat. No.: HY-N0619A

cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Daclizumab

(Zenapax; Ro 24-7375)

Cat. No.: HY-108738

Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks **CD25** (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.

Daclizumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deacetylasperulosidic Acid

Cat. No.: HY-N0594

Deacetylasperulosidic acid (DAA) is a major phytochemical constituent of Morinda citrifolia fruit. Deacetylasperulosidic acidhas antioxidant activity by increasing superoxide dismutase activity.



Purity: 98.33%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 20 mg

Deoxyandrographolide

Cat. No.: HY-N0857

Deoxyandrographolide suppresses LPS induced increase in mRNA levels of iNOS as well as production of proinflammatory mediators TNF-α and IL-6. Deoxyandrographolide potentiates NGF-induced neurite outgrowth.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deucravacitinib

(BMS-986165)

Cat. No.: HY-117287

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric **TYK2** inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC_{50}=1.0 nM) and blocks receptor-mediated Tyk2 activation by...



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Dexanabinol

(HU-211)

Cat. No.: HY-106387

Dexanabinol (HU-211) is an artificially synthesized cannabinoid derivative and lacks cannabimimetic effects.



Purity: 98.60%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg

Di-O-methyldemethoxycurcumin

Cat. No.: HY-N7275

Di-O-methyldemethoxycurcumin, a curcuminoid analog, inhibits **IL-6** production with an EC_{50} of 16.20 μg/mL. Anti-inflammatory and antioxidant properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Diacerein

(Diacerhein; Diacetylrhein)

Cat. No.: HY-N0283

Diacerein (Diacerhein), a interleukin-1 beta inhibitor, is a slow-acting medicine of the class anthraquinone used to treat joint diseases.



Purity: 98.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Disulfiram

(Tetraethylthiuram disulfide; TETD)

Cat. No.: HY-B0240

Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of **aldehyde-dehydrogenase (ALDH1)**, used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dupilumab

(REGN-668; SAR-231893) Cat. No.: HY-P9926

Dupilumab (REGN-668) is a fully human mAb to **IL-4 receptor α (IL-4Rα)** that inhibits both **IL-4** and **IL-13** signaling, markedly improved moderate-to-severe atopic dermatitis.

Dupilumab

Purity: ≥96.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Elubrixin

(SB-656933) Cat. No.: HY-18263A

Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active **CXCR2** antagonist and an **IL-8 receptor** antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC_{50} of 260.7 nM) and shape change (IC_{50} of 310.5 nM).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Elubrixin tosylate

(SB-656933 tosylate) Cat. No.: HY-18263C

Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active **CXCR2** antagonist and an **IL-8 receptor** antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC_{50} of 260.7 nM) and shape change (IC_{50} of 310.5 nM).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Episappanol

Cat. No.: HY-N9315

Episappanol is a natural compound isolated from Caesalpinia sappan heartwood with anti-inflammatory activity. Episappanol significantly inhibits the **IL-6** and **TNF-α** secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Etokimab

(Antibody ANB 020) Cat. No.: HY-P99018

Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis.

Etokimab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gamma-glutamylcysteine TFA

(γ-Glutamylcysteine TFA) Cat. No.: HY-113402A

Gamma-glutamylcysteine (γ-Glutamylcysteine) TFA, an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

GIBH-130

Cat. No.: HY-101860

GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the **IL-1β** secretion by activated microglia (IC_{50}=3.4 nM).



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ginsenoside F3

Cat. No.: HY-N0600

Ginsenoside F3, a component of PPTGs (an minor saponin in the leaves of Panax ginseng), has immunoenhancing activity by regulating production and gene expression of type 1 cytokines (IL-2, IFN-gamma) and type 2 cytokines (IL-4 and IL-10).



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Ginsenoside Rc

(Panaxoside Rc) Cat. No.: HY-N0042

Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptor$_A$ (**$GABA_A$**)-mediated ion channel currents (I_{GABA}). Ginsenoside Rc inhibits the expression of **TNF-α** and **IL-1β**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rh1

(Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1) Cat. No.: HY-N0604

Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of **PPAR-γ**, **TNF-α**, **IL-6**, and **IL-1β**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GP130 receptor agonist-1

Cat. No.: HY-121488

GP130 receptor agonist-1 is a potent, brain-penetrant and orally active **GP130 receptor** agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Guselkumab

(CNTO 1959)

Cat. No.: HY-P9931

Guselkumab is a recombinant human IgG1 monoclonal antibody against the **IL-23p19 subunit**. Guselkumab binds to human and cynomolgus monkey IL-23 with K_d values of 3.3 and 1.9 pmol/L, respectively.

Guselkumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydrocortisone hemisuccinate

(Hydrocortisone 21-hemisuccinate)

Cat. No.: HY-B1402

Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-inflammatory drug (SAID).



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Hydrocortisone phosphate

(Hydrocortisone 21-phosphate; Cortisol 21-phosphate)

Cat. No.: HY-B1155

Hydrocortisone phosphate (Hydrocortisone 21-phosphate), a physiological glucocorticoid, and is an orally active steroidal anti-inflammatory drug (SAID).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

IL-15-IN-1

Cat. No.: HY-102049

IL-15-IN-1 is a potent and selective **Interleukin 15 (IL-15)** inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC_{50} of 0.8 μM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IL-17 modulator 1

Cat. No.: HY-141535

IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17 modulator 1 disodium

Cat. No.: HY-141535A

IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IL-17 modulator 3

Cat. No.: HY-139203

IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17 modulator 4

Cat. No.: HY-141692

IL-17 modulator 4 is a prodrug of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IL-17 modulator 4 sulfate

Cat. No.: HY-141692A

IL-17 modulator 4 sulfate is a prodrug of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17 modulator 5

Cat. No.: HY-145434

IL-17 modulator 5 (compound 26) is a **IL-17** inhibitor, with an **IC_{50}** of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17 modulator 6

Cat. No.: HY-144373

IL-17 modulator 6 (compound 61) is a potent **Interleukin 17 (IL-17) modulator (pIC_{50}=9.1). IL-17 modulator 6 has the ability to inhibit IL-17 and can be used for the treatment of inflammatory and autoimmune diseases.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17A antagonist 1

Cat. No.: HY-101913

IL-17A antagonist 1 (compound 1) is an **IL-17A** antagonist, with a **K_d** of 0.66 μM and an **IC_{50}** of 1.14 μM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

IL-17A antagonist 3

Cat. No.: HY-101915

IL-17A antagonist 3 is an **IL-17A** antagonist, compound 3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17A inhibitor 1

Cat. No.: HY-139206

IL-17A inhibitor 1 (example 24) is a **IL-17A** inhibitor, with **IC_{50}** values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IL-17A inhibitor 2

Cat. No.: HY-139686

IL-17A inhibitor 2 is an **IL-17A** inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17A modulator-1

Cat. No.: HY-145430

IL-17A modulator-1 is a **IL-17A** modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a **pIC_{50}** of 8.2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IL-17A modulator-2

Cat. No.: HY-145429

IL-17A modulator-2 is a **IL-17A** modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a **pIC_{50}** of 8.3.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IL-4-inhibitor-1

Cat. No.: HY-139092

IL-4-inhibitor-1 (compound 52) is an **IL-4** inhibitor, with an **EC_{50}** of 1.81 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

iNOs-IN-1

Cat. No.: HY-145846

iNOs-IN-1 (YPW) is a potent inducible nitric oxide synthase (**iNOS**) inhibitor. iNOs-IN-1 can significantly inhibit the expression of IL-6 and iNOS, as well as reduce LPS-induced NO generation with dose-dependent manner in mouse macrophages. Anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Interleukin (IL)-6 Receptor

Cat. No.: HY-P0317

Interleukin (IL)-6 Receptor is a peptide, derived from interleukin-6 receptor.

TSLPVQDSSSVP

Purity: 98.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Isoforskolin

(Coleonol B)

Cat. No.: HY-N6927

Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely **TNF-α**, **IL-1β**, **IL-6** and **IL-8**, in human mononuclear leukocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IX 207-887

Cat. No.: HY-106087

IX 207-887 is a novel antiarthritic agent which inhibits the release of **interleukin-1** (**IL-1**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ixekizumab

(LY2439821)

Cat. No.: HY-P9924

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin **IL-17A** (K_D<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members.

Ixekizumab

Purity: 98.90%
Clinical Data: Launched
Size: 1 mg, 5 mg

JTE-607

Cat. No.: HY-110133

JTE-607, a highly selective **inflammatory cytokine synthesis** inhibitor, protects from endotoxin shock in mice.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Kaempferol 3-O-β-D-glucuronide

(Kaempferol-3-glucuronide; Kaempferol-3-O-glucuronide)

Cat. No.: HY-N7176

Kaempferol 3-O-β-D-glucuronide (Kaempferol-3-glucuronide), one conjugated kaempferol metabolite, has anti-inflammatory effect.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Kansuinine A

Cat. No.: HY-126421

Kansuinine A inhibits IL-6-induced Stat3 activation. Kansuinine A possesses antiviral and anticancer activity.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kansuinine B

Cat. No.: HY-126420

Kansuinine B inhibits IL-6-induced Stat3 activation. Kansuinine B possesses anti-viral activity and could be used in the study for COVID-19.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Lipoxin A4

(LXA4)

Cat. No.: HY-113509

Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 μg

Lipoxin A4-d5

(LXA4-d5)

Cat. No.: HY-113509S

Lipoxin A4-d5 (LXA4-d5) is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and **anti-inflammatory** properties.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 μg

LMT-28

Cat. No.: HY-102084

LMT-28 is an orally active and the first synthetic **IL-6** inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lyn peptide inhibitor

Cat. No.: HY-P1111

Lyn peptide inhibitor is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyn peptide inhibitor TFA

Cat. No.: HY-P1111A

Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Madecassic acid

Cat. No.: HY-N0569

Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by **iNOS**, **COX-2**, **TNF-alpha**, **IL-1beta**, and **IL-6** inhibition via the downregulation of **NF-κB** activation in RAW 264.7 macrophage cells.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Methylthiouracil

(MTU)

Cat. No.: HY-B0513

Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production **TNF-α** and **IL-6**, and the activation of **NF-κB** and **ERK1/2**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mulberroside A

Cat. No.: HY-N0619

Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.).



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Muscone

Cat. No.: HY-N0633

Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits **NF-κB** and **NLRP3** inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (**IL-1β**, **TNF-α** and **IL-6**), and ultimately improves cardiac function and survival rate.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Negletein

(5,6-Dihydroxy-7-methoxyflavone)

Cat. No.: HY-N4285

Negletein is a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. Negletein shows promising anti-inflammatory activity via inhibition of **TNF-α** and **IL-1β** with IC_{50} values of 16.4 and 10.8 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Neochlorogenic acid

(trans-5-O-Caffeoylquinic acid)

Cat. No.: HY-N0722

Neochlorogenic acid is a natural polyphenolic compound found in dried fruits and other plants. Neochlorogenic acid inhibits the production of **TNF-α** and **IL-1β**. Neochlorogenic acid suppresses **iNOS and COX-2** protein expression.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NFAT Transcription Factor Regulator-1

Cat. No.: HY-112778

NFAT Transcription Factor Regulator-1 is an **IL-2 synthesis** inhibitor with an IC_{50} of 182 nM.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NO-prednisolone

(NCX-1015) Cat. No.: HY-101757

NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone. NO-prednisolone potently stimulates **IL-10** production in vivo.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Nosantine racemate

(NPT 15392 racemate) Cat. No.: HY-101687

Nosantine racemate is the racemate of Nosantine. Nosantine is an inducer of **IL-2** or enhancer of **IL-2** induction by phytohemagglutinin (PHA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ossirene

(AS101) Cat. No.: HY-101019

Ossirene (AS101), an immunomodulatory tellurium compound, is a potent **IL-1β** inhibitor. Ossirene abolishes phosphorylation of STAT3 by inhibiting **IL-10**. Ossirene potently inhibits **Caspase-1** and is used for the autoimmune diseases and certain malignancies.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

PDE4-IN-8

Cat. No.: HY-144684

PDE4-IN-8 (Example 5) is a potent **PDE4** inhibitor with an IC_{50} of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC_{50}=4.04 nM), IL4 (IC_{50}=36.33 nM), IFNy (IC_{50}=2394 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pectolinarin

Cat. No.: HY-N0314

Pectolinarin possesses anti-inflammatory activity. Pectolinarin inhibits secretion of **IL-6** and **IL-8**, as well as the production of **PGE2** and **NO**. Pectolinarin suppresses cell proliferation and inflammatory response and induces **apoptosis** via inactivation of the **PI3K/Akt** pathway.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

PNRI-299

Cat. No.: HY-15131

PNRI-299 is a selective **AP-1** transcription inhibitor with an IC_{50} of 20 uM. PNRI-299 is a selective **APE/Ref-1** inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ppc-1

Cat. No.: HY-117843

Ppc-1 is a **mitochondrial** uncoupler. Ppc-1 enhances **mitochondrial** oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate **interleukin-2 (IL-2)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RCGD423

Cat. No.: HY-114775

RCGD423 is a **gp130** modulator, which prevents articular cartilage degeneration and promotes repair.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Resatorvid

(TAK-242; CLI-095) Cat. No.: HY-11109

Resatorvid (TAK-242) is a selective **Toll-like receptor 4 (TLR4)** inhibitor. Resatorvid inhibits **NO, TNF-α** and **IL-6** production with IC_{50s} of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Reslizumab

(Sch 55700) Cat. No.: HY-P9949

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target **interleukin-5 (IL-5)** for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of **IL-5**.

Purity: ≥99.4%
Clinical Data: Launched
Size: 1 mg, 2 mg

RO2959 hydrochloride

Cat. No.: HY-113618A

RO2959 hydrochloride is a potent and selective **CRAC channel** inhibitor with an IC_{50} of 402 nM. RO2959 hydrochloride is a potent blocker of **store operated calcium entry (SOCE)** mediated by **Orai1/Stim1 channels** with an IC_{50} of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

RO2959 monohydrochloride

Cat. No.: HY-113618B

RO2959 monohydrochloride is a potent and selective **CRAC channel** inhibitor with an IC_{50} of 402 nM. RO2959 monohydrochloride is a potent blocker of **store operated calcium entry (SOCE)** mediated by **Orai1/Stim1 channels** with an IC_{50} of 25 nM.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RP-54745

Cat. No.: HY-101716

RP-54745 is an inhibitor of macrophage stimulation and **interleukin-1** production, and a potential antirheumatic compound.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Sarilumab

(Anti-Human IL6Rα, Human Antibody)

Cat. No.: HY-P9916

Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a **interleukin-6 (IL-6) receptor** antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation.

Sarilumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

SC144

Cat. No.: HY-15614

SC144 is a first-in-class, orally active **gp130 (IL6-beta)** inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC144 hydrochloride

Cat. No.: HY-15614A

SC144 hydrochloride is a first-in-class, orally active **gp130 (IL6-beta)** inhibitor.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SDZ 224-015

Cat. No.: HY-141622

SDZ 224-015 is an orally active inhibitor of the **interleukin-1 beta (IL-1β)** converting enzyme and **caspase-1**. SDZ 224-015 possesses anti-COVID-19 activity, targeting M^{pro} (IC_{50} of 30 nM).
.



Purity: 95.49%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Secukinumab

(AIN457)

Cat. No.: HY-P9927

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against **interleukin (IL)-17A**. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

Secukinumab

Purity: ≥99.20%
Clinical Data: Launched
Size: 1 mg, 5 mg

Semapimod tetrahydrochloride

(CNI-1493; CPSI-2364 tetrahydrochloride)

Cat. No.: HY-15509A

Semapimod tetrahydrochloride (CNI-1493), an inhibitor of **proinflammatory cytokine** production, can inhibit **TNF-α**, **IL-1β**, and **IL-6**. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC_{50}≈0.3 μM).



Purity: 98.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sodium thiocyanate

(Thiocyanate sodium)

Cat. No.: HY-23119

Sodium thiocyanate reduces plasma levels of the pro-inflammatory cytokine **IL-6**, and increases the anti-inflammatory cytokine **IL-10** levels. Sodium thiocyanate also significantly reduces of **ROS** formation.

NaSCN

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

SP4206

Cat. No.: HY-119424

SP4206 is an **IL-2/IL-2Rα interaction** inhibitor. SP4206 binds with high affinity (K_d=70 nM) to **IL-2** and blocks binding to its natural receptor **IL-2Rα** (K_d=10 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SU5201

Cat. No.: HY-21293

SU5201 is an inhibitor of interleukin-2 (**IL-2**) production.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Suplatast (Tosilate)

(IPD 1151T)

Cat. No.: HY-17002

Suplatast Tosilate (IPD 1151T) is an orally active **Th2 cytokine** inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Tocilizumab

(Anti-Human IL6R, Humanized Antibody)

Cat. No.: HY-P9917

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (**IL-6R**) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling.

Tocilizumab

Purity: 99.67%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Triptoquinone B

((+)-Triptoquinone B)

Cat. No.: HY-N1120

Triptoquinone B ((+)-Triptoquinone B), a sesquiterpene alkaloid, is an **interleukin-1** inhibitor. Triptoquinone B shows potent inhibitory activities against interleukin 1α and β releases for human peripheral mononuclear cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Tyrphostin A1

(Tyrphostin 1; AG9)

Cat. No.: HY-16668

Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

Ustekinumab

(Anti-Human IL-12/IL-23, Human Antibody)

Cat. No.: HY-P9909

Ustekinumab is an anti-**IL-12/IL-23** IgG1κ human monoclonal antibody.

Ustekinumab

Purity: 98.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 25 mg, 50 mg

Veledimex

(INXN-1001; RG-115932)

Cat. No.: HY-16785

Veledimex (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system.



Purity: 99.19%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Veledimex (S enantiomer)

(INXN-1001 (S enantiomer); RG-115932 (S enantiomer))

Cat. No.: HY-16785B

Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for **CYP3A4/5**.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Veledimex racemate

(INXN-1001 racemate; RG-115932 racemate)

Cat. No.: HY-16785A

Veledimex racemate (INXN-1001 racemate) is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.



Purity: 97.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VGX-1027

(GIT 27)

Cat. No.: HY-15507

VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10.



Purity: 99.93%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

Vidofludimus

(4sc-101; SC12267)

Cat. No.: HY-14908

Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.



Purity: 99.06%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Y-320

Cat. No.: HY-15898

Y-320 is a new phenylpyrazoleanilide immunomodulator; inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Y13g

Cat. No.: HY-115910

Y13g is the potent inhibitor of both **AChE** and **IL-6**. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g reverses the STZ-induced memory deficit, and shows histopathology similarly as in normal animals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM-90709

Cat. No.: HY-19969

YM-90709 is a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

YQ128

Cat. No.: HY-130252

YQ128 is a potent and selective second-generation **NLRP3 (NOD-like receptor P3) inflammasome** inhibitor with an IC_{50} of 0.30 μM. YQ128 significantly and selectively suppresses the production of **IL-1β**, but not TNF-α, and it can cross the BBB to reach the CNS.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

β-Anhydroicaritin

Cat. No.: HY-N1940

β-Anhydroicaritin is isolated from Boswellia carterii Birdware, has important biological and pharmacological effects, such as antiosteoporosis, estrogen regulation and antitumor properties.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg